RESULTS OF AN OPEN-LABEL COMPARATIVE RANDOMIZED CLINICAL TRIAL OF AXOGLATIRAN®  FS (F-SINTEZ, RUSSIA) EFFICIENCY AND SAFETY IN COMPARISON WITH COPAXONE®-TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

Open Label ◽

Relapsing Remitting ◽

Pharmaceutical Industries ◽

Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial

Frontiers in Behavioral Neuroscience ◽

10.3389/fnbeh.2016.00028 ◽

2016 ◽

Vol 10 ◽

Cited By ~ 11

Author(s):

Flavia Mattioli ◽

Fabio Bellomi ◽

Chiara Stampatori ◽

Leandro Provinciali ◽

Laura Compagnucci ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Cognitive Training ◽

Domain Specific ◽

Relapsing Remitting ◽

A non‐randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing‐remitting multiple sclerosis patients

Clinical and Translational Medicine ◽

10.1186/s40169-019-0228-7 ◽

2019 ◽

Vol 8 (1) ◽

Author(s):

Mehrdokht Mazdeh ◽

Shahriar Kargar Monhaser ◽

Mohammad Taheri ◽

Soudeh Ghafouri‐Fard

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Scale Score ◽

Expanded Disability Status Scale ◽

Disability Status ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽

LB003-MON ORAL NUTRACEUTICAL FORMULA (PLP10) FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS: DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL

Clinical Nutrition Supplements ◽

10.1016/s1744-1161(12)70661-0 ◽

2012 ◽

Vol 7 (1) ◽

pp. 266

Author(s):

I.S. Patrikios ◽

M.C. Pantzaris ◽

G.N. Loukaides ◽

E.E. Ntzani

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Double Blind ◽

Relapsing Remitting ◽

Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis – Randomized clinical trial

PLoS ONE ◽

10.1371/journal.pone.0230551 ◽

2020 ◽

Vol 15 (4) ◽

pp. e0230551

Author(s):

Tamiris Silva ◽

Yara Dadalti Fragoso ◽

Maria Fernanda Setúbal Destro Rodrigues ◽

Andréa Oliver Gomes ◽

Fernanda Cordeiro da Silva ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Interleukin 10 ◽

Relapsing Remitting ◽

Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: A double blind randomized clinical trial

Clinical Neurology and Neurosurgery ◽

10.1016/j.clineuro.2012.02.039 ◽

2012 ◽

Vol 114 (7) ◽

pp. 986-989 ◽

Cited By ~ 8

Author(s):

Shahriar Nafissi ◽

Amirreza Azimi ◽

Ali Amini-Harandi ◽

Shiva Salami ◽

Mohammad Amir shahkarami ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Side Effects ◽

Interferon Beta ◽

Double Blind ◽

Relapsing Remitting ◽

Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial

American Journal of Clinical Nutrition ◽

10.3945/ajcn.113.075309 ◽

2015 ◽

Vol 101 (3) ◽

pp. 487-495 ◽

Cited By ~ 30

Author(s):

Anja Mähler ◽

Jochen Steiniger ◽

Markus Bock ◽

Lars Klug ◽

Nadine Parreidt ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Metabolic Response ◽

Relapsing Remitting ◽

The effects of modified anti-inflammatory diet on fatigue, quality of life, and inflammatory biomarkers in relapsing-remitting multiple sclerosis patients: a randomized clinical trial

International Journal of Neuroscience ◽

10.1080/00207454.2020.1750398 ◽

2020 ◽

pp. 1-9

Author(s):

Zahra Mousavi-Shirazi-Fard ◽

Zohreh Mazloom ◽

Sadegh Izadi ◽

Mohammad Fararouei

Keyword(s):

Quality Of Life ◽

Multiple Sclerosis ◽

Clinical Trial ◽

Inflammatory Biomarkers ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽

Methodology of EARLIMS Study: A Multi-Center, Open-Label, Non-Randomized, Parallel Group Clinical Trial To Assess the Efficacy of Fingolimod in Treatment-Naive Patients Versus Fingolimod in Patients Previously Treated with Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients with Relapsing-Remitting Multiple Sclerosis (P04.126)

Neurology ◽

10.1212/wnl.78.1_meetingabstracts.p04.126 ◽

2012 ◽

Vol 78 (Meeting Abstracts 1) ◽

pp. P04.126-P04.126

Author(s):

X. Montalban ◽

O. Fernandez ◽

A. L. Gobartt

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Glatiramer Acetate ◽

Open Label ◽

Parallel Group ◽

Relapsing Remitting ◽

Treatment Naïve ◽

Previously Treated ◽

Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy

Neurological Sciences ◽

10.1007/s10072-016-2701-z ◽

2016 ◽

Vol 38 (1) ◽

pp. 53-59 ◽

Cited By ~ 15

Author(s):

Alice Laroni ◽

Davide Brogi ◽

Vincenzo Brescia Morra ◽

Leonello Guidi ◽

Carlo Pozzilli ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Trial ◽

Open Label ◽

Relapsing Remitting ◽

EVOLVE-MS-1: a phase 3, open-label, long-term safety study of ALKS 8700 in relapsing-remitting multiple sclerosis

10.26226/morressier.59a3edabd462b8028d8952fe ◽

2017 ◽

Author(s):

Robert T. Naismith

Keyword(s):

Multiple Sclerosis ◽

Open Label ◽

Safety Study ◽

Phase 3 ◽

Relapsing Remitting ◽